Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA seeks injunction against N.J. supplement firms

This article was originally published in The Tan Sheet

Executive Summary

Following an FDA investigation, the Department of Justice files a complaint for permanent injunction against Patterson, N.J., businessman Mohamed S. Desoky and his supplement firms - Quality Formulation Laboratories Inc., American Sports Nutrition Inc. and Sports Nutrition International LLC - for failing to "correct filthy conditions" or to declare the presence of allergens in products. The complaint, filed July 1 in the U.S. District Court for New Jersey, alleges the firms failed to meet good manufacturing practices after an FDA inspection found unclean processing equipment and "live and dead rodents and rodent urine, feces and gnaw holes on bags of product." According to a July 10 FDA release, because the firms failed to make corrections an injunction is needed to stop them from manufacturing and distributing products until corrections are made. FDA said Desoky's firms manufacture supplements and protein powders sold in the U.S. and export products for private-label customers





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts